New mAb therapies in multiple myeloma: Interference with blood transfusion compatibility testing

Current Opinion in Hematology

Volumn 23, Issue 6, 2016, Pages 557-562

  De Vooght, Karen M K ^a   Oostendorp, Marlies ^a   Van Solinge, Wouter W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

blood transfusion; indirect antiglobulin test; interference; mAb therapy; multiple myeloma

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD38 ANTIGEN; DARATUMUMAB; DITHIOTHREITOL; ANTINEOPLASTIC AGENT; BLOOD GROUP ABO SYSTEM; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; BLOOD COMPATIBILITY; BLOOD TRANSFUSION; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COUGHING; DIZZINESS; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEVER; GENOTYPE; HEALTH CARE PERSONNEL; HUMAN; INFUSION RELATED REACTION; LABORATORY TEST; MULTIPLE MYELOMA; NAUSEA; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; UMBILICAL CORD BLOOD CELL; ANTAGONISTS AND INHIBITORS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; CROSS REACTION; IMMUNOLOGY; METABOLISM; PROCEDURES; STANDARDS;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; CROSS REACTIONS; ERYTHROCYTES; HUMANS; MULTIPLE MYELOMA;

EID: 84978154089     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000276     Document Type: Review

References (15)

1. Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: Overview of the preclinical and clinical development. Ther Adv Hematol 2015; 6:120-127.
2. Magarotto V, Salvini M, Bonello F, et al. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. Leuk Lymphoma 2016; 57:537-556.
3. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016; 270:95-112.
4. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016; 387:1551-1560.
5. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015; 55:1555-1562.
6. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015; 55:1545- 1554.
7. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373:1207-1219.
8. Raje N, Longo DL. Monoclonal antibodies in multiple myeloma come of age. N Engl J Med 2015; 373:1264-1266.
9. McKeage K. Daratumumab: First global approval. Drugs 2016; 76:275- 281.
10. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 2016; 127:681-695.
11. Chillemi A, Zaccarello G, Quarona V, et al. CD38 and bone marrow microenvironment. Front Biosci (Landmark Ed) 2014; 19:152- 162.
12. Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion 2015; 55:2770.
13. De Vooght KM, Oostendorp M, van Solinge WW. Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing. Transfusion 2016; 56:778-779.
14. McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: Teasing out monoclonal antibody interference. Clin Chem Lab Med 2016; 54:1095-1104.
15. Schmidt AE, Kirkley S, Patel N, et al. An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab. Transfusion 2015; 55:2292-2293.